Literature DB >> 20583448

Usefulness of laparoscope-assisted antrectomy for gastric carcinoids with hypergastrinemia.

Masato Hoshino1, Nobuo Omura, Fumiaki Yano, Kazuto Tsuboi, Akira Matsumoto, Se Ryung Yamamoto, Syunsuke Akimoto, Hideyuki Kashiwagi, Katsuhiko Yanaga.   

Abstract

The mechanisms responsible for development of gastric carcinoid tumors (type I carcinoids) in type A atrophic gastritis are hyperplasia of enterochromaffin-like cells that are associated with hypergastrinemia, and tumorigenesis. Endoscopic resection and gastrectomy are applied as treatment modalities for gastric carcinoids associated with gastrin hypersecretion. However, since the underlying pathology is the hyperplasia of gastrin-secreting cells and over-production of gastrin in the antropyloric region, antrectomy seems a logical treatment modality. To date, we have performed laparoscopic-assisted anterectomies in 3 cases of type I gastric carcinoid. The lesions have regressed or disappeared in 2 cases, in which resections of the foci were not performed. Furthermore, no has been observed in the other case, in which laparoscopic resection was performed. A laparoscopic antrectomy for type I gastric carcinoid is a minimally invasive treatment relevant to the pathology of the disease, and it is also expected to produce regression or even spontaneous resolution of the tumor.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20583448

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  8 in total

Review 1.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors.

Authors:  Ting-Ting Li; Feng Qiu; Zhi Rong Qian; Jun Wan; Xiao-Kun Qi; Ben-Yan Wu
Journal:  World J Gastroenterol       Date:  2014-01-07       Impact factor: 5.742

2.  A clinical perspective on gastric neuroendocrine neoplasia.

Authors:  Ben Lawrence; Mark Kidd; Bernhard Svejda; Irvin Modlin
Journal:  Curr Gastroenterol Rep       Date:  2011-02

Review 3.  [Gastric neuroendocrine tumors. Endoscopic and surgical treatment].

Authors:  M B Niederle; B Niederle
Journal:  Chirurg       Date:  2011-07       Impact factor: 0.955

4.  Recurrent gastric neuroendocrine tumors treated with total gastrectomy.

Authors:  Myounghwa Jung; Jung-Wook Kim; Jae-Young Jang; Young Woon Chang; Sun Hee Park; Yong Ho Kim; Youn Wha Kim
Journal:  World J Gastroenterol       Date:  2015-12-14       Impact factor: 5.742

5.  Response and relapse rates after treatment with long-acting somatostatin analogs in multifocal or recurrent type-1 gastric carcinoids: A systematic review and meta-analysis.

Authors:  Roberta Elisa Rossi; Pietro Invernizzi; Vincenzo Mazzaferro; Sara Massironi
Journal:  United European Gastroenterol J       Date:  2019-11-22       Impact factor: 4.623

Review 6.  Gastric neuroendocrine neoplasms and precursor lesions: Case reports and literature review.

Authors:  Alina Boeriu; Daniela Dobru; Crina Fofiu; Olga Brusnic; Danusia Onişor; Simona Mocan
Journal:  Medicine (Baltimore)       Date:  2022-01-14       Impact factor: 1.817

7.  Current concepts on gastric carcinoid tumors.

Authors:  George C Nikou; Theodoros P Angelopoulos
Journal:  Gastroenterol Res Pract       Date:  2012-12-17       Impact factor: 2.260

8.  Netazepide, a gastrin receptor antagonist, normalises tumour biomarkers and causes regression of type 1 gastric neuroendocrine tumours in a nonrandomised trial of patients with chronic atrophic gastritis.

Authors:  Andrew R Moore; Malcolm Boyce; Islay A Steele; Fiona Campbell; Andrea Varro; D Mark Pritchard
Journal:  PLoS One       Date:  2013-10-01       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.